These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 2183724)

  • 41. What can we expect down the road?
    Sullivan J
    Nephrol News Issues; 2011 Apr; 25(4):28-9. PubMed ID: 21542511
    [No Abstract]   [Full Text] [Related]  

  • 42. Helping patients with end-stage renal disease.
    Kuchta K; VanBuskirk S; Houglum M
    Am J Nurs; 2007 May; 107(5):35-6. PubMed ID: 17443073
    [No Abstract]   [Full Text] [Related]  

  • 43. Laboratory end-stage renal disease testing.
    Mesaros F
    Clin Lab Manage Rev; 1999; 13(3):132-6. PubMed ID: 10557874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2003 and inclusion of registered nurses in the personnel provision of the critical access hospital emergency services requirement for frontier areas and remote locations. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2002 Dec; 67(251):79965-80184. PubMed ID: 12510665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coordination of care in disease management: opportunities and financial issues.
    Mosley C
    Semin Dial; 2000; 13(6):346-50. PubMed ID: 11130253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The 2011 ESRD prospective payment system: an uncontrolled experiment.
    Winkelmayer WC; Chertow GM
    Am J Kidney Dis; 2011 Apr; 57(4):542-6. PubMed ID: 21333428
    [No Abstract]   [Full Text] [Related]  

  • 47. Risk-adjustment system for the Medicare capitated ESRD program.
    Levy JM; Robst J; Ingber MJ
    Health Care Financ Rev; 2006; 27(4):53-69. PubMed ID: 17290658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The 2011 ESRD prospective payment system: perspectives from Fresenius Medical Care, a large dialysis organization.
    Lacson E; Hakim RM
    Am J Kidney Dis; 2011 Apr; 57(4):547-9. PubMed ID: 21333423
    [No Abstract]   [Full Text] [Related]  

  • 49. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
    Lowrie EG; Hampers CL
    N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. International Study of Health Care Organization and Financing for end-stage renal disease in France.
    Durand-Zaleski I; Combe C; Lang P
    Int J Health Care Finance Econ; 2007 Sep; 7(2-3):171-83. PubMed ID: 17680359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medicare's end-stage renal disease program: current status and future prospects.
    Nissenson AR; Rettig RA
    Health Aff (Millwood); 1999; 18(1):161-79. PubMed ID: 9926654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The new reimbursement regulations.
    Hanson K
    Nephrol Nurse; 1983; 5(5):17, 20. PubMed ID: 6358927
    [No Abstract]   [Full Text] [Related]  

  • 53. The future of the end-stage renal disease program.
    Paganini EP
    Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):12-5. PubMed ID: 1626551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).
    Dor A; Pauly MV; Eichleay MA; Held PJ
    Int J Health Care Finance Econ; 2007 Sep; 7(2-3):73-111. PubMed ID: 17653860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bundling and its potential impact on dialysis service providers.
    Sullivan J
    Nephrol News Issues; 2008 Oct; 22(11):12, 14, 16-7. PubMed ID: 19009855
    [No Abstract]   [Full Text] [Related]  

  • 56. The first DRG: lessons from the end stage renal disease program for the prospective payment system.
    Maxwell JH; Sapolsky HM
    Inquiry; 1987; 24(1):57-67. PubMed ID: 2951335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re-engineering the ESRD Program amid Medicare reform.
    Neumann ME
    Nephrol News Issues; 2005 Jan; 19(2):40-1. PubMed ID: 15717573
    [No Abstract]   [Full Text] [Related]  

  • 58. The 2011 ESRD prospective payment system: perspectives from a for-profit small- to medium-sized dialysis organization.
    Bhat P; Bhat JG
    Am J Kidney Dis; 2011 Apr; 57(4):556-8. PubMed ID: 21316132
    [No Abstract]   [Full Text] [Related]  

  • 59. Moving toward a patient-centered payment system for ESRD beneficiaries.
    Augustine BA
    Nephrol News Issues; 2004 May; 18(6):35. PubMed ID: 15160418
    [No Abstract]   [Full Text] [Related]  

  • 60. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
    Nissenson AR; Mayne TJ; Krishnan M
    Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.